News - Biotechnology


Current filters:


Popular Filters

1927 to 1951 of 2106 results

Novel disease-modifying therapies will drive MS market to $11.5 billion in 2015


The launch of several premium-priced novel disease-modifying therapies, including four oral agents, will…

BiotechnologyGlobalMarkets & MarketingNeurologicalPharmaceutical

Executive appointments at Merck & Co, Actelion and Jazz Pharma


US drug giant Merck & Co (NYSE: MRK) has appointed Cuong Viet Do as chief strategy officer, effective…

ActelionBiotechnologyJazz PharmaceuticalsManagementMerck & CoPharmaceutical

Mesoblast and Lonza establish strategic global manufacturing alliance for stem cell products


Australian regenerative medicine company Mesoblast (ASX: MSB) and Switzerland-based Lonza Group (SWS:…


Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development


In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurologicalNewron PharmaPharmaceutical

US leadership in global biomedical industry vulnerable to international competition


The USA still holds a commanding position in the biomedical field, but countries across Europe and Asia…

BiotechnologyFinancialNorth AmericaPharmaceuticalResearch

High demand for monoclonal antibodies will drive therapeutic proteins market


The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered…

AmgenBiotechnologyGlobalMarkets & MarketingNovo NordiskPharmaceuticalRoche

Australian Senate Committee rejects ban on gene patents


Australia’s pharma and biotech industries breathed a sigh of relief, when a Private Members Bill…


Pfizer invests $200 million in its Grange Castle, Ireland, facility


Pfizer (NYSE: PFE), the world’s leading pharmaceutical company, is to make a substantial investment…


Glycotope enrolls first patient for “biobetter” of Roche cancer drug Herceptin


Berlin, Germany-based glycomics specialist Glycotope GmbH says it has enrolled the first patients in…


Amgen’s Prolia increases bone mineral density over eight; new indications approved


The world’s largest biotechnology firm, USA-based Amgen (Nasdaq: AMGN) says that new long-term data…


Ongoing supply problems for Genzyme’s Cerezyme


US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Merck KGaA has another stab at multiple sclerosis, gaining rights to Peptimmune PI-2301 program


German drug major Merck KGaA (MRK: DE) is taking another look at the multiple sclerosis market, where…

BiotechnologyImmunologicalsLicensingMerck KGaANeurologicalPeptimmunePharmaceutical

US President signs America Invents Act, overhauling patent system


After nearly a decade of legislative efforts, US President Barack Obama on Friday (September 16) signed…

BiotechnologyNorth AmericaPatentsPharmaceuticalPolitics

Over 900 biotech medicines in development in USA, targeting more than 100 diseases


The USA’s biopharmaceutical research companies have 901 biotechnology medicines and vaccines in…

BiotechnologyNorth AmericaResearch

Prosensa to get milestone payments from GSK under Duchenne collaboration


Dutch biotech company Prosensa, focusing on rare diseases with an unmet medical need, has agreed with…

BiotechnologyFinancialGlaxoSmithKlineLicensingPharmaceuticalProsensaRare diseasesResearch

VBI Vaccines acquires Epixis and its innovative eVLP vaccine platform


USA-based, privately-held biotechnology company VBI Vaccines said yesterday that it has completed the…

BiotechnologyEpixisMergers & AcquisitionsVaccinesVBI Vaccines

USTR Embraces “TEAM” approach in TPP talks; Senators back 12-year exclusivity for biologics


September 12 marked the beginning of the eighth round of Trans-Pacific Partnership (TPP) negotiations,…

BiotechnologyGenericsGlobalNorth AmericaPatentsPharmaceuticalPolitics

Merck & Co and China’s BGI confirm strategic collaboration on biomarkers and genomic technologies


Under a previously-signed statement of intent, US drugs giant Merck & Co (NYSE: MRK), and China-based…

BGIBiotechnologyLicensingMerck & CoPharmaceuticalResearch

Substitution of brand name tacrolimus with generic proves safe for transplant recipients


The substitution of a brand name immunosuppressive drug with a generic (manufactured by Novartis generics…

Astellas PharmaBiotechnologyGenericsImmunologicalsPrografResearchtacrolimus

One-third of changes to clinical trial protocols are avoidable, says Tufts CSDD


Nearly 60% of all protocols used in clinical trials for new drugs are amended during the trial. Moreover,…

BiotechnologyNorth AmericaPharmaceuticalRegulationResearch

Genentech files with US FDA for vismodegib in rare form of advanced skin cancer


In a second filing for a novel skin cancer drug this year, Swiss drug major Roche (ROG: SIX) US subsidiary…

BiotechnologyCurisGenentechNorth AmericaOncologyPharmaceuticalRegulationRochevismodegib

InterMune’s IPF drug Esbriet sees first European launch, in Germany


US biotech firm InterMune (Nasdaq: ITMN) has announced that Esbriet (pirfenidone) will be offered to…

BiotechnologyEsbrietEuropeInterMuneMarkets & MarketingPharmaceuticalRespiratory and Pulmonary

SMC backs Celgene’s Vidaza for rare blood and bone marrow cancers in Scotland


The Scottish Medicines Consortium (SMC), the equivalent of the UK’s drug watchdog the National Institute…


1927 to 1951 of 2106 results

Company Spotlight



Back to top